title: Forced diuresis with matched hydration in reducing acute kidney injury during transcatheter aortic valve implantation (Reduce-AKI): study protocol for a randomized sham-controlled trial.
abstract: BACKGROUND
  Acute kidney injury (AKI) is observed in up to 41% of patients undergoing transcatheter aortic valve implantation (TAVI) and is associated with increased risk for mortality. The aim of the present study is to evaluate whether furosemide-induced diuresis with matched isotonic intravenous hydration using the RenalGuard system reduces AKI in patients undergoing TAVI.
  
  
  METHODS
  Reduce-AKI is a randomized sham-controlled study designed to examine the effect of an automated matched hydration system in the prevention of AKI in patients undergoing TAVI. Patients will be randomized in a 1:1 fashion to the RenalGuard system (active group) versus non-matched saline infusion (sham-controlled group). Both arms receive standard overnight saline infusion and N-acetyl cysteine before the procedure.
  
  
  CONCLUSIONS
  The Reduce-AKI trial will investigate whether the use of automated forced diuresis with matched saline infusion is an effective therapeutic tool to reduce the occurrence of AKI in patients undergoing TAVI.
  
  
  BACKGROUND
  Clinicaltrials.gov: NCT01866800, 30 April 30 2013.
authors.forename: Yaron
authors.initials: Y
authors.lastname: Arbel
authors.affiliation: Department of Cardiology, Tel-Aviv Medical Center affiliated to the Sackler Faculty of Medicine, Tel-Aviv University, 6 Weizman Street, Tel Aviv, Israel. eyalbe@tlvmc.gov.il.
authors.forename: Eyal
authors.initials: E
authors.lastname: Ben-Assa
authors.forename: Amir
authors.initials: A
authors.lastname: Halkin
authors.forename: Gad
authors.initials: G
authors.lastname: Keren
authors.forename: Arie Lorin
authors.initials: AL
authors.lastname: Schwartz
authors.forename: Ofer
authors.initials: O
authors.lastname: Havakuk
authors.forename: Eran
authors.initials: E
authors.lastname: Leshem-Rubinow
authors.forename: Maayan
authors.initials: M
authors.lastname: Konigstein
authors.forename: Arie
authors.initials: A
authors.lastname: Steinvil
authors.forename: Yigal
authors.initials: Y
authors.lastname: Abramowitz
authors.forename: Ariel
authors.initials: A
authors.lastname: Finkelstein
authors.forename: Shmuel
authors.initials: S
authors.lastname: Banai
mesh_terms: D000111:Acetylcysteine / Q000008:administration & dosage; D058186:Acute Kidney Injury / Q000139:chemically induced / Q000175:diagnosis / Q000517:prevention & control*; D000975:Antioxidants / Q000008:administration & dosage; D006328:Cardiac Catheterization / Q000009:adverse effects* / Q000379:methods; D002985:Clinical Protocols; D003287:Contrast Media / Q000009:adverse effects*; D017023:Coronary Angiography / Q000009:adverse effects*; D004231:Diuresis / Q000187:drug effects; D004232:Diuretics / Q000008:administration & dosage*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005440:Fluid Therapy; D005665:Furosemide / Q000008:administration & dosage*; D019918:Heart Valve Prosthesis Implantation / Q000009:adverse effects* / Q000379:methods; D006801:Humans; D007262:Infusions, Intravenous; D007557:Israel; D012107:Research Design; D012965:Sodium Chloride / Q000008:administration & dosage; D013997:Time Factors; D016896:Treatment Outcome; D014546:Urinary Catheterization
chemical_list: D000975:Antioxidants; D003287:Contrast Media; D004232:Diuretics; D012965:Sodium Chloride; D005665:Furosemide; D000111:Acetylcysteine